Skip to main content
Figure 5 | Radiation Oncology

Figure 5

From: [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes

Figure 5

distant disease free survival. The distant disease free survival (DDFS) rates are shown for recurrent (n = 15; blue solid line) and primary prostate cancer (n = 7; dashed line). The 2 and 3 year DDFS rates are 100% and 75% for primary, and 90% and 75% for recurrent tumours. The difference between primary and recurrent cancers is not significant (p = 0.51).

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us